Engineered Notch Receptors

Engineered Notch Receptors is a preclinical-stage cell therapy platform developed by Sanquinnovate for cancer immunotherapy, specifically targeting solid tumors. The platform utilizes synthetic or engineered Notch (synNotch) receptors to modulate the Notch signaling pathway. This technology allows for the conditional control of adoptive cell therapies, including CAR-T, TCR-T, and Tumor-Infiltrating Lymphocytes (TILs), by linking the detection of a specific antigen to the induction of a secondary therapeutic response. This "AND-gate" logic is designed to enhance the precision and safety of cell therapies in the complex microenvironment of solid tumors, potentially overcoming challenges such as off-target toxicity and immunosuppression.

Other names

Sanquinnovate Notch signaling cell therapysynNotch cell therapy